Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Faverio (Monza, Italy), G. Bonaiti (Monza, Italy), A. Stainer (Monza, Italy), F. De Giacomi (Monza, Italy), S. Zucchetti (Monza, Italy), B. Bodini (Novara, Italy), F. Bini (Garbagnate Milanese, Italy), A. Pesci (Monza, Italy). ABPA screening in bronchiectasis: is there a grey zone?. 2677

Member's Comments

No comment yet.

Related content which might interest you: Long term follow up of the lung function in cystic fibrosis patients with allergic bronchopulmonary aspergillosis (ABPA) Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 Demystifying fibrotic hypersensitivity pneumonitis diagnosis: it's all about shades of grey Source: Eur Respir J, 54 (1) 1900906; 10.1183/13993003.00906-2019 Year: 2019 Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012 Clinical cases: COPD and bronchiectasis Source: ERS Skills course - Biomarkers and functional assessment of obstructive lung diseases Year: 2017 Omalizumab for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in children with cystic fibrosis (CF) Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014 Is bronchiectasis really a disease? Source: Eur Respir Rev, 29 (155) 190051; 10.1183/16000617.0051-2019 Year: 2020 Accompanying asthma in cystic fibrosis (CF) and non-CF bronchiectatic patients: could we detect it with AMP bronchoprovocation and sputum properties? Source: Eur Respir J 2007; 30: Suppl. 51, 374s Year: 2007 Phenotyping bronchiectasis: is it all about sputum and infection? Source: Eur Respir J 2016; 47: 1037-1039 Year: 2016 Sputum colour: a useful clinical tool in non-cystic fibrosis bronchiectasis Source: Eur Respir J 2009; 33: 361-364 Year: 2009 Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease? Source: Eur Respir Rev 2010 19: 261-263 Year: 2010 Steroid sparing effect of anti-IgE antibody in allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis? Source: Eur Respir J, 55 (4) 1802465; 10.1183/13993003.02465-2018 Year: 2020 Definition and aetiology of non-CF bronchiectasis Source: Eur Respir Monogr 2013; 60: 107-119 Year: 2013 Is aspergillus isolation (without ABPA) associated with a decline in FEV1 in CF? Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Changes in total IgE levels predict pulmonary outcome in cystic fibrosis related allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Treatment to prevent exacerbations in bronchiectasis: macrolides as first line? Source: Eur Respir J, 54 (1) 1901213; 10.1183/13993003.01213-2019 Year: 2019 Diagnostic and therapeutic difficulties in pulmonary aspergillosis (PA) in paediatric cystic fibrosis (CF) patients Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006